<DOC>
	<DOCNO>NCT00074269</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine melphalan , donor peripheral blood stem cell transplant help stop growth tumor cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain tumor cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin , cyclosporine , methotrexate transplant may stop happen . PURPOSE : This phase II trial study well antithymocyte globulin , high-dose melphalan , fludarabine , allogeneic peripheral stem cell transplant work treat patient metastatic adenocarcinoma breast .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant After ATG , High-Dose Melphalan , Fludarabine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity tolerability allogeneic peripheral blood stem cell transplantation nonmyeloablative preparative regimen comprise anti-thymocyte globulin , high-dose melphalan , fludarabine woman chemotherapy-refractory poor-prognosis metastatic adenocarcinoma breast . - Determine ability preparative regimen facilitate long-term engraftment allogeneic stem cell lymphocytes patient . - Determine response measurable/evaluable disease temporal relationship preparative chemotherapy use onset clinical graft-versus-host disease ( GVHD ) patient treat regimen . Secondary - Determine progression-free overall survival patient treat regimen . - Determine tumor response temporal relationship administration high-dose chemotherapy onset GVHD patient treat regimen . - Determine frequency durability induction full donor chimerism lymphocytes patient treated regimen . OUTLINE : This nonrandomized , pilot study . - Nonmyeloablative preparative regimen : Patients receive fludarabine IV 30 minute day -8 -4 , anti-thymocyte globulin IV 4 hour day -7 -4 , high-dose melphalan IV 30 minute day -3 -2 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV ( orally tolerate ) every 12 hour begin day -4 taper day 42 ( GVHD occur ) day 90 ( grade I acute GVHD occurs ) . Patients also receive methotrexate IV day 1 , 3 , 6 . - Allogeneic peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo allogeneic PBSCT day 0 . Patients also receive filgrastim ( G-CSF ) IV subcutaneously begin day 0 continue blood count recover . - Donor lymphocyte infusion ( DLI ) : Patients show disease progression fail achieve full donor type T-cell chimerism ( least 90 % donor derive T-cells ) 90-day assessment posttransplantation , evidence active GVHD may receive DLI . Patients unresponsive disease active GVHD receive subsequent DLIs every 6-8 week . Patients follow 1 , 3 , 6 , 12 , 18 , 24 , 30 , 36 month . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease Meets 1 follow criterion : Chemotherapyunresponsive disease define 1 follow : Less partial response 2 consecutive chemotherapy regimen include anthracycline taxane combination succession Progression disease within 3 month completion taxane , anthracycline , platinolbased regimen Histologically confirm tumor involvement bone marrow biopsy Measurable evaluable disease* define follow : Bidimensionally reproducible measurable mass physical examination , ultrasonography , radiography , CT scan , MRI Evaluable lesion apparent clinical exam , xray , CT scan , MRI fit criterion measurability ( e.g. , illdefined postsurgical mass mass assessable 1 dimension ) Elevation biological marker ( e.g. , CA 27.29 ) consider evaluable disease NOTE : *Bone lesion pleural peritoneal effusion alone consider measurable evaluable disease Appropriate candidate allogeneic stem cell transplantation No active CNS metastases Available HLAidentical sibling donor 6/6 antigen match Donor CD34 cell least 2 time 10^6/kg recipient weight Hormone receptor status : Estrogen receptor negative positive Estrogen receptor positive tumor must demonstrate progression least 1 hormonal manipulation PATIENT CHARACTERISTICS : Age 18 60 Sex Female Menopausal status Not specify Performance status Karnofsky 70100 % OR ECOG 01 Life expectancy Not specify Hematopoietic WBC least 1,500/mm^3 Platelet count least 30,000/mm^3 Hepatic Bilirubin less 3 time normal* AST ALT less 3 time normal* NOTE : *Unless abnormality due malignancy Renal Creatinine great 1.6 mg/dL Cardiovascular LVEF great 40 % echocardiography MUGA No myocardial infarction within past 6 month Pulmonary DLCO great 40 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious localize systemic infection No hypersensitivity E. coliderived product No history nonbreast malignant disease within past 5 year except completely excise nonmelanoma skin cancer carcinoma situ cervix No chronic inflammatory disorder require concurrent glucocorticosteroids immunosuppressive medication No psychological condition social situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy No concurrent glucocorticoid Radiotherapy No prior radiotherapy indicator lesion unless lesion show evidence progression discontinuation therapy Surgery Not specify Other No concurrent immunosuppressive medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>